Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway
Myocardial fibrosis following acute myocardial infarction (AMI) seriously affects the prognosis and survival rate of patients. This study explores the role and regulation mechanism of storax, a commonly used traditional Chinese medicine for treatment of cardiovascular diseases, on myocardial fibrosi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657855/ https://www.ncbi.nlm.nih.gov/pubmed/36361958 http://dx.doi.org/10.3390/ijms232113161 |
_version_ | 1784829800954724352 |
---|---|
author | Xu, Zhuo Lu, Danni Yuan, Jianmei Wang, Liying Wang, Jiajun Lei, Ziqin Liu, Si Wu, Junjie Wang, Jian Huang, Lihua |
author_facet | Xu, Zhuo Lu, Danni Yuan, Jianmei Wang, Liying Wang, Jiajun Lei, Ziqin Liu, Si Wu, Junjie Wang, Jian Huang, Lihua |
author_sort | Xu, Zhuo |
collection | PubMed |
description | Myocardial fibrosis following acute myocardial infarction (AMI) seriously affects the prognosis and survival rate of patients. This study explores the role and regulation mechanism of storax, a commonly used traditional Chinese medicine for treatment of cardiovascular diseases, on myocardial fibrosis and cardiac function. The AMI rat model was established by subcutaneous injection of Isoproterenol hydrochloride (ISO). Storax (0.1, 0.2, 0.4 g/kg) was administered by gavage once/d for 7 days. Electrocardiogram, echocardiography, hemodynamic and cardiac enzyme in AMI rats were measured. HE, Masson, immunofluorescence and TUNEL staining were used to observe the degree of pathological damage, fibrosis and cardiomyocyte apoptosis in myocardial tissue, respectively. Expression of AT1R, CARP and their downstream related apoptotic proteins were detected by WB. The results demonstrated that storax could significantly improve cardiac electrophysiology and function, decrease serum cardiac enzyme activity, reduce type I and III collagen contents to improve fibrosis and alleviate myocardial pathological damage and cardiomyocyte apoptosis. It also found that storax can significantly down-regulate expression of AT1R, Ankrd1, P53, P-p53 (ser 15), Bax and cleaved Caspase-3 and up-regulate expression of Mdm2 and Bcl-2. Taken together, these findings indicated that storax effectively protected cardiomyocytes against myocardial fibrosis and cardiac dysfunction by inhibiting the AT1R–Ankrd1–P53 signaling pathway. |
format | Online Article Text |
id | pubmed-9657855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96578552022-11-15 Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway Xu, Zhuo Lu, Danni Yuan, Jianmei Wang, Liying Wang, Jiajun Lei, Ziqin Liu, Si Wu, Junjie Wang, Jian Huang, Lihua Int J Mol Sci Article Myocardial fibrosis following acute myocardial infarction (AMI) seriously affects the prognosis and survival rate of patients. This study explores the role and regulation mechanism of storax, a commonly used traditional Chinese medicine for treatment of cardiovascular diseases, on myocardial fibrosis and cardiac function. The AMI rat model was established by subcutaneous injection of Isoproterenol hydrochloride (ISO). Storax (0.1, 0.2, 0.4 g/kg) was administered by gavage once/d for 7 days. Electrocardiogram, echocardiography, hemodynamic and cardiac enzyme in AMI rats were measured. HE, Masson, immunofluorescence and TUNEL staining were used to observe the degree of pathological damage, fibrosis and cardiomyocyte apoptosis in myocardial tissue, respectively. Expression of AT1R, CARP and their downstream related apoptotic proteins were detected by WB. The results demonstrated that storax could significantly improve cardiac electrophysiology and function, decrease serum cardiac enzyme activity, reduce type I and III collagen contents to improve fibrosis and alleviate myocardial pathological damage and cardiomyocyte apoptosis. It also found that storax can significantly down-regulate expression of AT1R, Ankrd1, P53, P-p53 (ser 15), Bax and cleaved Caspase-3 and up-regulate expression of Mdm2 and Bcl-2. Taken together, these findings indicated that storax effectively protected cardiomyocytes against myocardial fibrosis and cardiac dysfunction by inhibiting the AT1R–Ankrd1–P53 signaling pathway. MDPI 2022-10-29 /pmc/articles/PMC9657855/ /pubmed/36361958 http://dx.doi.org/10.3390/ijms232113161 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xu, Zhuo Lu, Danni Yuan, Jianmei Wang, Liying Wang, Jiajun Lei, Ziqin Liu, Si Wu, Junjie Wang, Jian Huang, Lihua Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway |
title | Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway |
title_full | Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway |
title_fullStr | Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway |
title_full_unstemmed | Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway |
title_short | Storax Attenuates Cardiac Fibrosis following Acute Myocardial Infarction in Rats via Suppression of AT1R–Ankrd1–P53 Signaling Pathway |
title_sort | storax attenuates cardiac fibrosis following acute myocardial infarction in rats via suppression of at1r–ankrd1–p53 signaling pathway |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657855/ https://www.ncbi.nlm.nih.gov/pubmed/36361958 http://dx.doi.org/10.3390/ijms232113161 |
work_keys_str_mv | AT xuzhuo storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT ludanni storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT yuanjianmei storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT wangliying storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT wangjiajun storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT leiziqin storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT liusi storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT wujunjie storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT wangjian storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway AT huanglihua storaxattenuatescardiacfibrosisfollowingacutemyocardialinfarctioninratsviasuppressionofat1rankrd1p53signalingpathway |